Selected research
Industry Research
Central Nervous System (CNS) Therapeutics Industry Research Report 2026
Market perspective
The global Central Nervous System (CNS) Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Central Nervous System (CNS) Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Central Nervous System (CNS) Therapeutics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Central Nervous System (CNS) Therapeutics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Central Nervous System (CNS) Therapeutics include Biogen, UCB Pharma, Viatris, Eli Lilly, Roche, Merck & Co Inc, Novartis, Johnson and Johnson and Teva and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Central Nervous System (CNS) Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Central Nervous System (CNS) Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Central Nervous System (CNS) Therapeutics Market by Company
Biogen
UCB Pharma
Viatris
Eli Lilly
Roche
Merck & Co Inc
Novartis
Johnson and Johnson
Teva
Takeda
Central Nervous System (CNS) Therapeutics Segment by Type
CNS Trauma
Neurovascular Diseases
Neurodegenerative Diseases
Other
Central Nervous System (CNS) Therapeutics Segment by Application
Hospital
Online
Other
Central Nervous System (CNS) Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Central Nervous System (CNS) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Central Nervous System (CNS) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Central Nervous System (CNS) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Central Nervous System (CNS) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CNS Trauma
- Neurovascular Diseases
- Neurodegenerative Diseases
- Other
Applications
- Hospital
- Online
- Other
Companies covered
- Biogen
- UCB Pharma
- Viatris
- Eli Lilly
- Roche
- Merck & Co Inc
- Novartis
- Johnson and Johnson
- Teva
- Takeda
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Central Nervous System (CNS) Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 CNS Trauma
- 2.2.3 Neurovascular Diseases
- 2.2.4 Neurodegenerative Diseases
- 2.2.5 Other
- 2.3 Central Nervous System (CNS) Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Online
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Central Nervous System (CNS) Therapeutics Breakdown Data by Type
- 3.1 Global Central Nervous System (CNS) Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Central Nervous System (CNS) Therapeutics Forecasted Market Size by Type (2027-2032)
4 Central Nervous System (CNS) Therapeutics Breakdown Data by Application
- 4.1 Global Central Nervous System (CNS) Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Central Nervous System (CNS) Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Central Nervous System (CNS) Therapeutics Market Perspective (2021-2032)
- 5.2 Global Central Nervous System (CNS) Therapeutics Growth Trends by Region
- 5.2.1 Global Central Nervous System (CNS) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Central Nervous System (CNS) Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Central Nervous System (CNS) Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Central Nervous System (CNS) Therapeutics Market Dynamics
- 5.3.1 Central Nervous System (CNS) Therapeutics Industry Trends
- 5.3.2 Central Nervous System (CNS) Therapeutics Market Drivers
- 5.3.3 Central Nervous System (CNS) Therapeutics Market Challenges
- 5.3.4 Central Nervous System (CNS) Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Central Nervous System (CNS) Therapeutics Players by Revenue
- 6.1.1 Global Top Central Nervous System (CNS) Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Central Nervous System (CNS) Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Central Nervous System (CNS) Therapeutics Head Office and Area Served
- 6.4 Global Central Nervous System (CNS) Therapeutics Players, Product Type & Application
- 6.5 Global Central Nervous System (CNS) Therapeutics Manufacturers Established Date
- 6.6 Global Central Nervous System (CNS) Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Central Nervous System (CNS) Therapeutics Market Size (2021-2032)
- 7.2 North America Central Nervous System (CNS) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Central Nervous System (CNS) Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Central Nervous System (CNS) Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Central Nervous System (CNS) Therapeutics Market Size (2021-2032)
- 8.2 Europe Central Nervous System (CNS) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Central Nervous System (CNS) Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Central Nervous System (CNS) Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Central Nervous System (CNS) Therapeutics Market Size (2021-2032)
- 10.2 South America Central Nervous System (CNS) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Central Nervous System (CNS) Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Central Nervous System (CNS) Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Central Nervous System (CNS) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Biogen
- 12.1.1 Biogen Company Information
- 12.1.2 Biogen Business Overview
- 12.1.3 Biogen Revenue in Central Nervous System (CNS) Therapeutics Business (2021-2026)
- 12.1.4 Biogen Central Nervous System (CNS) Therapeutics Product Portfolio
- 12.1.5 Biogen Recent Developments
- 12.2 UCB Pharma
- 12.2.1 UCB Pharma Company Information
- 12.2.2 UCB Pharma Business Overview
- 12.2.3 UCB Pharma Revenue in Central Nervous System (CNS) Therapeutics Business (2021-2026)
- 12.2.4 UCB Pharma Central Nervous System (CNS) Therapeutics Product Portfolio
- 12.2.5 UCB Pharma Recent Developments
- 12.3 Viatris
- 12.3.1 Viatris Company Information
- 12.3.2 Viatris Business Overview
- 12.3.3 Viatris Revenue in Central Nervous System (CNS) Therapeutics Business (2021-2026)
- 12.3.4 Viatris Central Nervous System (CNS) Therapeutics Product Portfolio
- 12.3.5 Viatris Recent Developments
- 12.4 Eli Lilly
- 12.4.1 Eli Lilly Company Information
- 12.4.2 Eli Lilly Business Overview
- 12.4.3 Eli Lilly Revenue in Central Nervous System (CNS) Therapeutics Business (2021-2026)
- 12.4.4 Eli Lilly Central Nervous System (CNS) Therapeutics Product Portfolio
- 12.4.5 Eli Lilly Recent Developments
- 12.5 Roche
- 12.5.1 Roche Company Information
- 12.5.2 Roche Business Overview
- 12.5.3 Roche Revenue in Central Nervous System (CNS) Therapeutics Business (2021-2026)
- 12.5.4 Roche Central Nervous System (CNS) Therapeutics Product Portfolio
- 12.5.5 Roche Recent Developments
- 12.6 Merck & Co Inc
- 12.6.1 Merck & Co Inc Company Information
- 12.6.2 Merck & Co Inc Business Overview
- 12.6.3 Merck & Co Inc Revenue in Central Nervous System (CNS) Therapeutics Business (2021-2026)
- 12.6.4 Merck & Co Inc Central Nervous System (CNS) Therapeutics Product Portfolio
- 12.6.5 Merck & Co Inc Recent Developments
- 12.7 Novartis
- 12.7.1 Novartis Company Information
- 12.7.2 Novartis Business Overview
- 12.7.3 Novartis Revenue in Central Nervous System (CNS) Therapeutics Business (2021-2026)
- 12.7.4 Novartis Central Nervous System (CNS) Therapeutics Product Portfolio
- 12.7.5 Novartis Recent Developments
- 12.8 Johnson and Johnson
- 12.8.1 Johnson and Johnson Company Information
- 12.8.2 Johnson and Johnson Business Overview
- 12.8.3 Johnson and Johnson Revenue in Central Nervous System (CNS) Therapeutics Business (2021-2026)
- 12.8.4 Johnson and Johnson Central Nervous System (CNS) Therapeutics Product Portfolio
- 12.8.5 Johnson and Johnson Recent Developments
- 12.9 Teva
- 12.9.1 Teva Company Information
- 12.9.2 Teva Business Overview
- 12.9.3 Teva Revenue in Central Nervous System (CNS) Therapeutics Business (2021-2026)
- 12.9.4 Teva Central Nervous System (CNS) Therapeutics Product Portfolio
- 12.9.5 Teva Recent Developments
- 12.10 Takeda
- 12.10.1 Takeda Company Information
- 12.10.2 Takeda Business Overview
- 12.10.3 Takeda Revenue in Central Nervous System (CNS) Therapeutics Business (2021-2026)
- 12.10.4 Takeda Central Nervous System (CNS) Therapeutics Product Portfolio
- 12.10.5 Takeda Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst